Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,645 stopped studies mapped to Malignant Lung Neoplasm and descendants · 90% state a reason
Over the 1,645 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel… | Phase 1 / Phase 2 | terminated | Oct 5, 2007 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00559897 | Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced… | Phase 2 | terminated | Nov 16, 2007 | Barbara Ann Karmanos Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT00818675 | A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat… | Phase 2 | terminated | Jan 8, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01046383 | Effect of IMN1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small… | Phase 3 | terminated | Jan 12, 2010 | Immunotec Inc. | Slower than anticipated recruitment | Enrollment / accrual |
| NCT02297425 | A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer | Phase 2 | withdrawn | Nov 21, 2014 | Pfizer | not stated | Not stated |
| NCT00511576 | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for… | Phase 1 | terminated | Aug 6, 2007 | Mirati Therapeutics Inc. | Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All… | Other (stated, no rule matched) |
| NCT00975767 | A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced… | Phase 1 | terminated | Sep 11, 2009 | Mirati Therapeutics Inc. | The study was terminated due to a need for a reformulation of the study drug. Phase 1 completed, no… | Enrollment / accrual |
| NCT01160731 | Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With… | Phase 1 | withdrawn | Jul 12, 2010 | Cancer Trials Ireland | not stated | Not stated |
| NCT01761747 | Ponatinib for Squamous Cell Lung and Head and Neck Cancers | Phase 2 / Phase 3 | terminated | Jan 7, 2013 | Dana-Farber Cancer Institute | FDA hold and toxicity associated with study drug | Safety / toxicity |
| NCT01336543 | Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III… | Phase 2 | withdrawn | Apr 18, 2011 | Syed Jafri | Low accrual, small patient population at center. | Enrollment / accrual |
| NCT00452075 | Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for… | Phase 2 | terminated | Mar 26, 2007 | Rigshospitalet, Denmark | Poor recruitment | Enrollment / accrual |
| NCT01664663 | Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis…(PLANET) | Phase 2 | terminated | Aug 14, 2012 | Ass. Prof. Jan Nyman | Safety analysis showed increased grade 5 toxicity in experimental arm. | Safety / toxicity |
| NCT01038037 | First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer(Lung-TRIO) | Phase 2 | terminated | Dec 23, 2009 | Vejle Hospital | 1. Very low enrollment rate. 2. Recent studies question the effect of adding panitumumab in this… | Safety / toxicity |
| NCT00549328 | Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer | Phase 2 | terminated | Oct 25, 2007 | GlaxoSmithKline | Study enrolment was delayed in starting and too slow to support further development in this setting | Enrollment / accrual |
| NCT00726986 | Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell… | Phase 2 | terminated | Aug 1, 2008 | Afshin Dowlati, MD | Extreme toxicity | Safety / toxicity |
| NCT01799161 | Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients… | Phase 1 | withdrawn | Feb 26, 2013 | Eckhard Podack | Insufficient funding | Funding |
| NCT00300885 | A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel… | Phase 3 | terminated | Mar 10, 2006 | Bayer | Based on the results of the interim analysis, it was determined that the study would not meet its… | Efficacy / futility |
| NCT00108186 | Celecoxib Treatment for Lung Cancer | Phase 1 | withdrawn | Apr 15, 2005 | US Department of Veterans Affairs | Couldn't accrue patients | Enrollment / accrual |
| NCT01313663 | A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in… | Phase 2 | terminated | Mar 14, 2011 | GlaxoSmithKline | not stated | Not stated |
| NCT01049776 | GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line | Phase 2 | terminated | Jan 14, 2010 | Illinois CancerCare, P.C. | Study was terminated due to positive results seen in statistical analysis. Adequate patient… | Enrollment / accrual |
| NCT02127372 | Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 | Phase 1 / Phase 2 | terminated | Apr 30, 2014 | Duke University | The study was closed due to poor accrual | Enrollment / accrual |
| NCT00509366 | Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV…(TOP0602) | Phase 2 | terminated | Jul 31, 2007 | Duke University | Study terminated due to reproducibility issues with genomics prediction model. | Other (stated, no rule matched) |
| NCT02209727 | Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic… | Phase 1 | terminated | Aug 6, 2014 | Boehringer Ingelheim | not stated | Not stated |
| NCT00787852 | A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung… | Phase 1 | terminated | Nov 10, 2008 | Brown University | for efficacy and safety reasons | Safety / toxicity |
| NCT01938456 | Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects… | Phase 1 | withdrawn | Sep 10, 2013 | GlaxoSmithKline | This study was Cancelled Before Active | Other (stated, no rule matched) |
| NCT00373204 | Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin… | Phase 2 | terminated | Sep 7, 2006 | Pharmacyclics LLC. | not stated | Not stated |
| NCT00907699 | Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on… | — | withdrawn | May 22, 2009 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01913067 | Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer…(CRANIAL) | Phase 2 | withdrawn | Jul 31, 2013 | Jules Bordet Institute | Scientific rationale is deemed obsolete. Funders lost interest in the trial. | Other (stated, no rule matched) |
| NCT00545948 | Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage…(TOP0703) | Phase 2 | terminated | Oct 18, 2007 | Duke University | Study terminated due to reproducibility issues with genomics prediction model. | Other (stated, no rule matched) |
| NCT01491633 | Dasatinib in Advanced Squamous Cell Lung Cancer | Phase 2 | terminated | Dec 14, 2011 | Dana-Farber Cancer Institute | Safety issues/concerns per DF/HCC PI | Safety / toxicity |
| NCT01187615 | Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With… | Phase 1 | terminated | Aug 24, 2010 | Bayer | not stated | Not stated |
| NCT02157116 | Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung… | Phase 2 | terminated | Jun 5, 2014 | Duke University | Insufficient accrual to meet analysis goals | Enrollment / accrual |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | Phase 1 | terminated | Mar 26, 2004 | Yale University | not stated | Not stated |
| NCT00145418 | Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer | Phase 2 | terminated | Sep 5, 2005 | Oncology Specialists, S.C. | low enrollment | Enrollment / accrual |
| NCT00898209 | Serum and Exhaled Breath Condensate MALDI-MS of Lung Cancer. (SPORE) | — | terminated | May 12, 2009 | Vanderbilt-Ingram Cancer Center | This study competed with another VICC study | Other (stated, no rule matched) |
| NCT00907504 | Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In…(ADVIGO1017) | Phase 3 | withdrawn | May 22, 2009 | Pfizer | not stated | Not stated |
| NCT00528775 | Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung… | Phase 2 | terminated | Sep 12, 2007 | Roswell Park Cancer Institute | drug cannot be prepared commercially | Other (stated, no rule matched) |
| NCT00544648 | Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg… | Phase 1 / Phase 2 | terminated | Oct 16, 2007 | Vanderbilt-Ingram Cancer Center | Ph I completed. Funding became unavailable causing Ph II to cease after two patients were enrolled. | Enrollment / accrual |
| NCT00004859 | Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients… | Phase 3 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Trial was stopped early for futility | Efficacy / futility |
| NCT00976677 | Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in… | Phase 2 | terminated | Sep 14, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01654081 | A Protocol of Irinotecan for Carcinoma of the Lung | Phase 2 | withdrawn | Jul 31, 2012 | Susanne Arnold | Slow accrual | Enrollment / accrual |
| NCT00084487 | Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or… | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00323362 | Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic… | Phase 2 | terminated | May 9, 2006 | Rutgers, The State University of New Jersey | Toxicity | Safety / toxicity |
| NCT00614484 | Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer | Phase 1 / Phase 2 | terminated | Feb 13, 2008 | Loma Linda University | Low participant enrollment rates. Significant comparative data not obtained. | Enrollment / accrual |
| NCT00313690 | Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer | Phase 1 / Phase 2 | withdrawn | Apr 12, 2006 | University of Southern California | Recruitment difficulties | Enrollment / accrual |
| NCT01471197 | Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell… | Phase 2 | terminated | Nov 15, 2011 | Bristol-Myers Squibb | Administrative reasons | Other (stated, no rule matched) |
| NCT02044601 | Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus… | Phase 1 / Phase 2 | withdrawn | Jan 24, 2014 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00088933 | Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With… | Phase 1 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00112060 | A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced… | Phase 1 / Phase 2 | withdrawn | May 30, 2005 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT00203931 | Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer | Phase 2 | terminated | Sep 20, 2005 | University of Chicago | Slow accrual and evidence from other studies showing benefit of early initiation of pemetrexed… | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 5, 2015source: clinicaltrials